Clinical Trial

Single-agent Capecitabine as Metronomic Chemotherapy in LAHNSCC (CMHN)

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to investigate whether the addition of metronomic capecitabine to the standard treatment can improve prognosis in locoregionally advanced head and neck squamous cell carcinoma.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2021-09-04; most recent amendment 2022-02-15.
Status change: Not Yet Recruiting → Recruiting 2022-02-15
Trial Details
NCT Number NCT05044117
Lead Sponsor Sun Yat-sen University
Collaborators: Fujian Medical University Union Hospital, Guangzhou Panyu Central Hospital, The Central Hospital of Yongzhou, Hunan University of Medicine General Hospital, Hanzhong Central Hospital, Yichang Central People's Hospital, Affiliated Hospital of Guangdong Medical University, Jiangmen Central Hospital, Xiangyang No.1 People's Hospital
Conditions Head and Neck Squamous Cell Carcinoma
Enrollment 220 participants
Start Date 2021-10-18
Primary Completion 2026-10 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2022-03-03